Related references
Note: Only part of the references are listed.Decreased Dolutegravir and Efavirenz Concentrations With Preserved Virological Suppression in Patients With Tuberculosis and Human Immunodeficiency Virus Receiving High-Dose Rifampicin
Christine Sekaggya-Wiltshire et al.
CLINICAL INFECTIOUS DISEASES (2023)
Continuous versus Intermittent Enteral Tube Feeding for Critically Ill Patients: A Prospective, Randomized Controlled Trial
Hong-Yeul Lee et al.
NUTRIENTS (2022)
Altered drug exposures of first-line TB drugs in a moxifloxacin- containing treatment regimen
R. Perumal et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2022)
High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial
Fiona Cresswell et al.
CLINICAL INFECTIOUS DISEASES (2021)
Plasma Pharmacokinetics of High-Dose Oral versus Intravenous Rifampicin in Patients with Tuberculous Meningitis: a Randomized Controlled Trial
Sean Wasserman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial
Anthony J. Garcia-Prats et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
Model-Based Meta-analysis of Rifampicin Exposure and Mortality in Indonesian Tuberculous Meningitis Trials
Elin M. Svensson et al.
CLINICAL INFECTIOUS DISEASES (2020)
Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus-associated tuberculosis
Charlotte Schutz et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)
A systematic review and meta-analysis of first-line tuberculosis drug concentrations and treatment outcomes
R. Perumal et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2020)
A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs
Alper Daskapan et al.
CLINICAL PHARMACOKINETICS (2019)
The critically ill patient with tuberculosis in intensive care: Clinical presentations, management and infection control
Akaninyene Otu et al.
JOURNAL OF CRITICAL CARE (2018)
Double-Blind, Randomized, Placebo-Controlled Phase II Dose-Finding Study To Evaluate High-Dose Rifampin for Tuberculous Meningitis
S. Dian et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses
Robin J. Svensson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction
Maxwell T. Chirehwa et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
A Dose-Ranging Trial to Optimize the Dose of Rifampin in the Treatment of Tuberculosis
Martin J. Boeree et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)
Pharmacokinetic/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis
Lindsey te Brake et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2015)
Burden of tuberculosis in intensive care units in Cape Town, South Africa, and assessment of the accuracy and effect on patient outcomes of the Xpert MTB/RIF test on tracheal aspirate samples for diagnosis of pulmonary tuberculosis: a prospective burden of disease study with a nested randomised controlled trial
Gregory L. Calligaro et al.
LANCET RESPIRATORY MEDICINE (2015)
Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin
C. Magis-Escurra et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2014)
Low rifampicin concentrations in tuberculosis patients with HIV infection
Tanuja N. Gengiah et al.
JOURNAL OF INFECTION IN DEVELOPING COUNTRIES (2014)
Drug absorption, distribution, metabolism and excretion considerations in critically ill adults
Derek J. Roberts et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2013)
Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial
Rovina Ruslami et al.
LANCET INFECTIOUS DISEASES (2013)
The pharmacokinetics of enteral antituberculosis drugs in patients requiring intensive care
C. F. N. Koegelenberg et al.
SAMJ SOUTH AFRICAN MEDICAL JOURNAL (2013)
Reduced Antituberculosis Drug Concentrations in HIV-Infected Patients Who Are Men or Have Low Weight: Implications for International Dosing Guidelines
Helen McIlleron et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
A Semimechanistic Pharmacokinetic-Enzyme Turnover Model for Rifampin Autoinduction in Adult Tuberculosis Patients
Wynand Smythe et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso
Nuccia Saleri et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients
Justin J. Wilkins et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Therapeutic drug monitoring in the treatment of active tuberculosis
Aylin Babalik et al.
CANADIAN RESPIRATORY JOURNAL (2011)
Mortality among patients with tuberculosis requiring intensive care: a retrospective cohort study
Denise R. Silva et al.
BMC INFECTIOUS DISEASES (2010)
Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA
Scott K. Heysell et al.
EMERGING INFECTIOUS DISEASES (2010)
Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption
Justin J. Wilkins et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin
Tawanda Gumbo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
The impact of admission diagnosis on gastric emptying in critically ill patients
Nam Q. Nguyen et al.
CRITICAL CARE (2007)
Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients
Justin J. Wilkins et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients
H McIlleron et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Effects of early enteral feeding on the outcome of critically ill mechanically ventilated medical patients
V Artinian et al.
CHEST (2006)
Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana
JW Tappero et al.
CLINICAL INFECTIOUS DISEASES (2005)
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease
P Gurumurthy et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Delayed treatment contributes to mortality in ICU patients with severe active pulmonary tuberculosis and acute respiratory failure
JR Zahar et al.
INTENSIVE CARE MEDICINE (2001)
Share Paper
